Justin Zelin Death ,Miami,FL Obituary,a respected Director and Senior Biotechnology Analyst at BTIG Has Passed Away
The biotechnology investment community is mourning the loss of Justin Zelin, a respected Director and Senior Biotechnology Analyst at BTIG, who was a vital intellectual force in Miami, Florida’s growing financial and life sciences sector. Zelin’s passing leaves a profound void in the field of equity research, where he was renowned for his deep expertise and bold, forward-looking analysis.
Based in Miami, Zelin specialized in cutting-edge therapeutic areas, including cell therapy, targeted oncology, and immunology. He provided essential market insights on a roster of innovative companies such as Viking Therapeutics, Syndax Pharmaceuticals, and Jasper Therapeutics. Known for his conviction, he was recognized for setting ambitious price targets and maintaining strong buy ratings on stocks he believed held transformative potential.
His career was built on a formidable academic and professional foundation. A proud alumnus of Harvard University, Zelin held both a bachelor’s in biology and a master’s in biotechnology. He brought a unique perspective to his role, with prior experience at biotech firm Agenus and over five years teaching at Harvard. His analytical path included positions at Canaccord Genuity, SVB Leerink, and B. Riley Securities before his pivotal role at BTIG.
More than just an analyst, Justin Zelin was a translator of complex science for the investment world. His rigorous research helped guide capital toward companies aiming to address some of medicine’s most challenging diseases. He will be remembered not only for his sharp intellect and track record but also as a dedicated figure who shaped the biotech investment dialogue. His legacy endures in the companies he championed and the colleagues he inspired.
